Kev daws qhov GLP-1 Supply Bottleneck: Premium Semaglutide Intermediate P29 (CAS 1169630-82-3)
Aug 07, 2026
Tso lus
Lub Pob Txha ntawm Kev Kho Mob Metabolic: Engineering Premium Semaglutide Intermediate P29 (CAS 1169630-82-3)
Kev Tshawb Fawb R & D ntawm Cov Khoom Siv -Phase Peptide Synthesis, GLP-1 Receptor Agonists, thiab Kev daws Lub Ntiaj Teb Supply Chain Bottleneck.
Txawm li cas los xij, lub ntiaj teb kev lag luam tab tom ntsib qhov muaj kev puas tsuaj loj: qhov hnyav, ntau - xyoo cov saw hlau tsis txaus. Qhov kev txwv tsis pub siv tsis yog cov neeg siv khoom xav tau, tab sis kev sib xyaw ua ke ntawm cov khoom siv tshuaj nquag.Tom ntej: Semaglutide Intermediate P29 (CAS 1169630-82-3)yog qhov tseem ceeb, tus nqi- txwv tsis pub cov khoom ua ntej yuav tsum tau sib sau ua ke GLP kawg-1 macromolecule. Kev lag luam B2B tam sim no tau tawm tsam nrog qis- tawm los, impurity-laden generic intermediates uas yuam R&D labs kom nres kev tsim khoom. Cov lus qhia ntxaws ntxaws no tau nthuav tawm cov txheej txheem molecular ntawm GLP-1 analogues, nthuav tawm cov kev phom sij zais cia ntawm crude peptide synthesis, thiab tsim kom muaj kev tsis sib haum xeeb, siab ncaj ncees cov txheej txheem tsim khoom siv ntawm Xi'an Tihealth.
1. Molecular Architecture: Yuav ua li cas GLP-1 Analogues Rewire Human Metabolism
Txhawm rau kom ua tiav qhov kev tsim cov Semaglutide, cov thawj coj ntawm kev yuav khoom thiab cov kws tshawb fawb tseem ceeb yuav tsum nkag siab tob txog cov hom phiaj cytological ntawm GLP-1 peptide ib ntus. Ntuj tib neeg GLP-1 yog degraded sai heev los ntawm cov enzyme dipeptidyl peptidase-4 (DPP-4), muab nws ib nrab- lub neej ntawm tsuas yog ob feeb. Cov qauv kev hloov kho nyob rau hauv Semaglutide-fais fab los ntawm kev sib koom ua ke ntawm P29 Intermediate-ntev no ib nrab-lub neej mus rau qhov xav tsis thoob 165 teev, tso cai rau noj ib zaug ib lim piam.
Pancreatic Beta-Cell Activation & Insulinotropic Action
Thaum txhaj tshuaj subcutaneous, cov sib sau ua ke Semaglutide peptide mus rau hauv lub txiav thiab xaiv khi rau GLP-1 receptors nyob rau saum npoo ntawm beta hlwb. Qhov kev khi no ua rau muaj zog, muaj suab thaj-dependant insulin secretion cascade. Tsis zoo li cov cuab yeej cuab tam sulfonylureas, Semaglutide tsuas yog ua rau cov tshuaj insulin tso tawm thaum cov ntshav qabzib nce siab, zoo li tshem tawm cov kev pheej hmoo ntawm kev tuag taus. Txoj kev tswj hwm kev txawj ntse no yog nyob ntawm qhov tseeb spatial folding ntawm cov saw peptide synthesized.
Gastric Emptying & Hypothalamic Satiety Signaling
Tshaj li glycemic tswj, Semaglutide macromolecule ua rau muaj txiaj ntsig zoo rau cov paj hlwb. Nws hla cov cheeb tsam tshwj xeeb ntawm cov ntshav- lub hlwb thaiv kev cuam tshuam nrog GLP-1 receptors hauv hypothalamus- lub hlwb kev noj qab haus huv chaw tswj hwm. Ib txhij, nws ncua lub physiological tus nqi ntawm gastric emptying. Qhov kev ua haujlwm thib ob no ua rau lub sijhawm ntev ntawm kev siv tshuab thiab paj hlwb satiety, ua rau nws yog cov cuab yeej siv tshuaj kho mob zoo tshaj plaws hauv kev sib ntaus tawm tsam kev rog rog.
Lub luag haujlwm tseem ceeb ntawm Intermediate P29
Semaglutide yog ib qho complex 31-amino acid polypeptide. Synthesizing xws li ib tug loj heev saws nyob rau hauv sequentially los ntawm kos tau nyob rau hauv kev puas tsuaj loj yield poob thiab uncontrollable impurity profiles. Yuav kom daws tau qhov no, kev tsim tshuaj siv tau los ntawm kev sib xyaw ua ke ntawm fragment synthesis.Tom ntej: Semaglutide Intermediate P29 (CAS 1169630-82-3)ua raws li qhov ua ntej- sib sau ua ke, kev txheeb xyuas cov pob txha loj. Los ntawm kev nrhiav ib qho P29 feem ntau ua kom huv si, cov chaw soj nstuam tuaj yeem txo qis lawv cov theem kev sib txuas, txiav lub sijhawm tsim khoom los ntawm lub lis piam, thiab xyuas kom meej API zaum kawg raws li FDA thiab EMA purity monographs.
2. Qhov Teeb Meem Ntawm Kev Tsim Nyog: Qhov Ncauj Tsis Txaus Siab ntawm Crude Peptide Synthesis
Qhov kev xav ua kom muaj txiaj ntsig ntawm GLP-1 boom tau ua rau dej nyab thoob ntiaj teb API kev lag luam nrog cov qauv tsis zoo, nrawm nrawm nrawm peptide intermediates. Rau cov macromolecule uas muag heev li Semaglutide, kev siv cov ntaub ntawv nyoos yog ib daim ntawv qhia rau kev tswj hwm kev puas tsuaj thiab muaj peev xwm tiv thaiv kab mob rau cov neeg mob.
Tsawg-tier manufacturers feem ntau siv archaic Liquid-Phase Peptide Synthesis (LPPS) los yog tsis zoo optimized Solid-Phase protocols. Cov txheej txheem no tsim kom muaj kev txaus ntshai ntawm cov impurities cuam tshuam:tshem tawm ib ntus(qhov twg cov amino acid hla dhau),insertion sequences(qhov twg ib qho ntxiv acid yog erroneously ntxiv), thiabD-amino acid racemization(qhov twg 3D orientation ntawm lub molecule flips). Vim tias cov impurities no yog cov txheej txheem yuav luag zoo ib yam rau lub hom phiaj P29 peptide, lawv tsis yooj yim rau kev sib cais. Yog tias qhov nruab nrab uas muaj cov txheej txheem tshem tawm raug siv los sib sau ua ke zaum kawg Semaglutide, nws tsim qhov hloov pauv GLP-1 analogue uas tuaj yeem ua rau muaj kev cuam tshuam autoimmune lossis anaphylaxis hauv tib neeg cov neeg mob.
3. Xi'an Tihealth Advantage: Siab -Fidelity Green Peptide Synthesis
NtawmXi'an Tihealth Biotechnology Co., Ltd., peb lees paub tias kev tsim cov 29-amino acid intermediate yuav tsum muaj kev paub txog biochemical kiag li. Thaum peptides tsis yog "cov nroj tsuag rho tawm," peb txoj kev cog lus rau kev nyab xeeb ua rau peb siv eco-tus phooj ywg, ntsuab catalysis raws tu qauv uas tshem tawm cov tshuaj lom neeg seem. Peb qhov chaw tsim khoom tsim khoom sawv cev rau qhov tseem ceeb ntawm cov niaj hnub bio-mimetic synthesis:
Precision SPPS Technology
Peb xa cov xeev - ntawm -the -art automated Solid-Phase Peptide Synthesis (SPPS) siv cov coupling reagents zoo heev. Qhov no tau lees paub qhov kev sib txuas siab tshaj plaws ntawm txhua txhua kauj ruam amino acid, ua kom muaj txiaj ntsig zoo ntawm kev tsim cov kev tshem tawm txaus ntshai thiab tiv thaiv chiral racemization.
Multi-Dimensional Prep-HPLC
Crude peptide cleavage inevitably tawm cov kab lus. Peb siv industrial-scale Preparative High-Performance Liquid Chromatography (Prep-HPLC) nrog rau cov theem tshwj xeeb nyob ruaj ruaj kom cais qhov tseeb P29 fragment, kom ntseeg tau tias peb cov khoom ua tiav tsis muaj kev cuam tshuam.Ntau dua lossis sib npaug rau 99.0% purity.
Advanced Lyophilization
Peptides yog qhov yooj yim heev rau thermal thiab oxidative degradation. Peb P29 intermediate tau dhau los ua nruj ultra- qhov kub thiab txias txias - ziab (lyophilization). Qhov no xauv lub molecular geometry nyob rau hauv ib tug ruaj khov dawb hmoov daim ntawv, ua rau kom lub txee zoo heev - lub neej thiab ua kom ntseeg tau tias kev thauj mus los thoob ntiaj teb.
4. Forensic Formulation Matrix: Xi'an Tihealth vs. Market Generics
Rau pawg neeg yuav khoom thiab cov thawj coj saib xyuas kev tshawb fawb, cov ntaub ntawv tsuas yog txiaj ntsig tseem ceeb. Sib piv cov forensic specifications ntawm peb P29 Intermediate tiv thaiv cov qauv kev lag luam muab:
| Analytical Parameter | Standard Generic Intermediates | Xi'an Tihealth P29 API (CAS 1169630-82-3) |
|---|---|---|
| Active Assay (HPLC Purity) | ~ 95.0% (Qhov kev pheej hmoo siab ntawm kev ua tsis tiav) | Ntau dua lossis sib npaug rau 99.0% (Tsev Kawm Ntawv Pharmaceutical Synthesis) |
| Ib qho siab kawg nkaus impurity | Feem ntau> 1.0% (muaj cov txheej txheem tshem tawm) | Tsawg dua los yog sib npaug li 0.5% (Strict LC-MS Verification) |
| Moisture (poob ntawm ziab) | Hloov pauv mus txog 8.0% (Risk ntawm hydrolysis) | Tsawg dua lossis sib npaug li 5.0% (Lyophilized Stability) |
| Trifluoroacetic Acid (TFA) Residue | Cov qib siab ntxiv los ntawm cleavage cocktail | Rigorous Salt Exchange (Acetate / HCl daim ntawv muaj) |
| Cov kab mob endotoxins | Feem ntau untested (tsis zoo rau txhaj tshuaj synthesis) | Kev soj ntsuam nruj me ntsis rau parenteral compounding kev nyab xeeb |
5. Muaj Scenarios rau Semaglutide Intermediates
Kev yuav peb cov Semaglutide Intermediate P29 uas tau lees paub zoo ua kom lub sijhawm- mus rau - kev ua lag luam thoob plaws ntau qhov xav tau tshuaj ntsug:
Kev lag luam GLP-1 API Manufacturing
Thawj daim ntawv thov. Los ntawm kev siv peb cov P29 cov saw tseem ceeb, CDMOs thiab API cov tuam txhab tuaj yeem hla qhov tsis ua haujlwm feem ntau - cov theem ntawm cov kab peptide synthesis, txhim kho qhov kawg ntawm Semaglutide tawm los thiab txo cov sijhawm ua haujlwm los ntawm lub lis piam.
Pharmaceutical R & D & Clinical Trials
Muab cov chaw soj ntsuam tshawb fawb nrog cov ntaub ntawv pov thawj, ultra- cov kab hauv paus dawb huv los tsim cov tshiab GLP-1/GIP dual-agonist analogues, tiv thaiv cov hauv paus impurities los ntawm skewing tseem ceeb hauv - cov ntaub ntawv vitro thiab in-vivo pharmacokinetic.
Formulator & Procurement FAQ
Semaglutide muaj aliphatic fatty acid spacer txuas rau lub ntsiab peptide qaum. Synthesizing tag nrho cov qauv no nyob rau hauv ib tug linear, kauj ruam - los ntawm - kauj ruam zam ua rau tag nrho cov yields tsis zoo thiab loj heev chemical pov tseg. Intermediate P29 (CAS 1169630-82-3) sawv cev rau cov tub ntxhais peptide sib xyaw ua ke zoo kawg nkaus. Cov neeg tsim khoom tuaj yeem ua tau zoo heev convergent coupling ntawm sab saw rau peb P29 nruab nrab, ua kom tiav cov Semaglutide molecule nrog ntau dua purity thiab kev lag luam muaj peev xwm.
Polypeptides yog rhiab heev rau thermal degradation thiab ya raws hydrolysis. Ua raws li peb cov txheej txheem lyophilization siab heev, API tam sim ntawd ntim rau hauv tsis muaj menyuam, tshuaj - qib kaw vials lossis ob npaug - txheej aseptic aluminium foil hnab hauv qab inert argon / nitrogen flush. Rau kev xa khoom thoob ntiaj teb, peb siv cov khoom txias txias-chain logistics (feem ntau yog 2℃txog 8℃lossis sib sib zog nqus- khov nyob ntawm cov neeg siv khoom tshwj xeeb) nrog rau qhov ntsuas kub tsis tu ncua- taug qab cov ntaub ntawv loggers.
kiag li. Xi'an Tihealth ua haujlwm nruj me ntsis hauv ISO9001: 2015 cov haujlwm. Txhua pawg xa tawm ntawm Semaglutide Intermediate P29 yog nrog los ntawm cov ntaub ntawv qhia ntxaws ntxaws. Qhov no suav nrog Daim Ntawv Pov Thawj Kev Ntsuam Xyuas (COA), siab -kev daws teeb meem HPLC chromatograms, Mass Spectrometry (MS) kev txheeb xyuas rau qhov hnyav molecular, thiab ua kom tiav cov khoom tsis huv los pab txhawb kev sib koom ua ke rau hauv koj DMF (Drug Master File) xa.
Ruaj ntseg koj cov saw hlau nrog cov kws tshuaj -qib GLP-1 peptide intermediates.
Thov HPLC Chromatogram & Bulk PricingSau los ntawm Wang Xueyan, Technical Operations & Formulation Strategy ntawm Xi'an Tihealth Biotechnology Co., Ltd.
* Kev lees paub tsis raug cai: Muab tshwj xeeb raws li qhov tsis muaj npe, kev tshawb fawb -qib Cov Tshuaj Siv Tshuaj (API) nruab nrab. Cov koom haum kev yuav khoom tsuas yog lub luag haujlwm rau kev tsim kho zaum kawg, kev sim tshuaj ntsuam xyuas, thiab kev tswj hwm nruj hauv lawv txoj cai thoob ntiaj teb.*
Xa kev nug